Abstract

Residual concentrations of erythromycin in food could result in gastrointestinal tract exposure that potentially poses a health-hazard to the consumer, affecting intestinal epithelial permeability, barrier function, microbiota composition, and antimicrobial resistance. We investigated the effects of erythromycin after acute (48 h single treatment with 0.03 μg/mL to 300 μg/mL) or chronic (repeated treatment with 0.3 µg/mL and 300 µg/mL erythromycin for five days) exposures on the permeability of human colonic epithelial cells, a model that mimics a susceptible intestinal surface devoid of commensal microbiota. Transepithelial electrical resistance (TER) measurements indicated that erythromycin above 0.3 µg/mL may compromise the epithelial barrier. Acute exposure increased cytotoxicity, while chronic exposure decreased the cytotoxicity. Quantitative PCR analysis revealed that only ICAM1 (intercellular adhesion molecule 1) was up-regulated during 0.3 μg/mL acute-exposure, while ICAM1, JAM3 (junctional adhesion molecule 3), and ITGA8 (integrin alpha 8), were over-expressed in the 300 μg/mL acute treatment group. However, during chronic exposure, no change in the mRNA expression was observed at 0.3 μg/mL, and only ICAM2 was significantly up-regulated after 300 μg/mL. ICAM1 and ICAM2 are known to be involved in the formation of extracellular matrices. These gene expression changes may be related to the immunoregulatory activity of erythromycin, or a compensatory mechanism of the epithelial cells to overcome the distress caused by erythromycin due to increased permeability.

Highlights

  • Erythromycin, a member of the macrolide antimicrobials, has been widely used in humans and animals for the treatment of a number of bacterial infections for Gram-positive cocci and Gram-negative cocci, besides mycoplasma infections [1,2]

  • The lowest concentration of erythromycin (0.03 μg/mL) did not reveal any any chachnagnegsesininththeeTTEERR dduurrininggthteheenetinreti4re8 h48pehripoder. iIondc.onIntracsot,nattra48sth, atitm4e8phoitnitm, eerypthorionmt,yecrinyt3h0r0omycin 300 μg/μmg/LmaLnadnd0.03.3μμgg/m/mLL ttrreeaatteeddwwelelsllsshsohwoewd esdignsiifgicnainfitcdaenctredaseecr(epa

  • This study used a comprehensive approach to evaluate the effects of exposure to erythromycin on intestinal permeability, cytotoxicity, and expression of related genes in an in vitro model of the human intestinal epithelium

Read more

Summary

Introduction

Erythromycin, a member of the macrolide antimicrobials, has been widely used in humans and animals for the treatment of a number of bacterial infections for Gram-positive cocci and Gram-negative cocci, besides mycoplasma infections [1,2]. If withdrawal times for clearance of this antimicrobial are not strictly followed, excessive exposure to erythromycin and its metabolites to the GIT can occur, raising questions about potential effects on human health [9,10]. AHE and other erythromycin metabolites are known to be microbiologically inactive; an in vitro study showed that AHE inhibits the oxidation function of Cytochrome P450 more efficiently than the erythromycin itself [12]. This inhibitory function may decrease drug clearance in the tissue, resulting in tissue accumulation, and be a mechanism for drug-induced toxicity

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call